This paper reviews the market of biotechnological drugs that show a higher collection to the General Social Security System in Health, according to the demographic and epidemiological profile of the Colombian population. It also highlights the importance of competition in the pharmaceutical biotechnology industry by granting greater access to the population, reducing the prices of these products and, consequently, favoring the health sector finances.